BRAF and neoplasm: Third, our detailed investigations provided insights into the potential effect of immune status within the tumor microenvironment on treatment outcomes in mCRC and explored characteristics of alterations acquired following treatment with BRAF inhibitor plus an anti-EGFR monoclonal antibody, with or without a MEK inhibitor, versus chemotherapy plus anti-EGFR therapy.